تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
DexCom, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $32.2B | |
|---|---|---|
| Revenue (ttm) | 5B | |
| Net income (ttm) | 999.7M | |
| EPS (ttm) | $2.54 | |
| Shares out | 377.4M | |
| P/E (trailing) | 30.9x | |
| P/E (forward) | 28.3x | |
| Volume | 3,965,269 | |
| Beta | 1.48 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.45B | $2.91B | $3.62B | $4.03B | $4.66B | +17.5% |
| Gross profit | $1.68B | $1.88B | $2.29B | $2.44B | $2.80B | +13.6% |
| Operating income | $265.8M | $391.2M | $597.7M | $600.0M | $911.8M | +36.1% |
| Net income | $216.9M | $341.2M | $541.5M | $576.2M | $836.3M | +40.1% |
| EPS (diluted) | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 | +40.9% |
| EBITDA | $377.5M | $565.3M | $916.7M | $945.7M | $1.36B | +37.7% |
| R&D | $517.1M | $484.2M | $505.8M | $552.4M | $599.1M | +3.7% |
| SG&A | $810.5M | $1.01B | $1.19B | $1.29B | $1.29B | +12.3% |
Recent company headlines from major financial publishers.
The modal base case incorporates solid commercial execution, gradual adoption across core diabetes segments, and successful integration with automated insulin delivery partners Tandem and Beta Bionics. Operating leverage advances steadily as manufacturing line efficiencies offset competitive pricing pressures, yielding a present intrinsic fair value of $58.97.
Under the bull scenario, favorable reimbursement expansion into non-intensive diabetes broadens the accessible patient population significantly, while automated manufacturing yields at the newly commissioned Ireland facility accelerate operating leverage. Sensor migration to extended-wear formats lowers unit production costs, expanding free cash flow generation annually.
| Ke ↓ / g → | 2.5% | 2.8% | 3.0% | 3.3% | 3.5% |
|---|---|---|---|---|---|
| 9.2% | $63.0 | $63.8 | $64.7 | $65.7 | $66.8 |
| 9.7% | $60.2 | $60.9 | $61.7 | $62.5 | $63.4 |
| 10.2% | $57.7 | $58.3 | $59.0 | $59.7 | $60.4 |
| 10.7% | $55.5 | $56.0 | $56.6 | $57.2 | $57.8 |
| 11.2% | $53.5 | $54.0 | $54.5 | $55.0 | $55.5 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
